The use of polymers in drug half-life extension has gained significant attention in the pharmaceutical industry as a strategy to improve the efficacy and patient compliance of therapeutic drugs. By attaching biocompatible polymers, such as polyethylene glycol (PEG), to drug molecules, it is possible to create polymer-drug conjugates that reduce the rate at which the drug is eliminated from the body. This polymer conjugation effectively extends the drug’s half-life, allowing for less frequent dosing and enhanced therapeutic outcomes. The extended half-life also minimizes side effects by maintaining more consistent drug levels in the bloodstream. As a result, the application of polymers in drug half-life extension holds great promise in the development of long-acting treatments for chronic conditions such as cancer, diabetes, and autoimmune diseases.